Hexamethylene bisacetamide

Hexamethylene bisacetamide

• Product Name Alternative: HMBA
• CAS Number: 3073-59-4
• UNSPSC Description: Hexamethylene bisacetamide (HMBA) is a differentiation inducer and selective bromine domain inhibitor that can differentiate across the blood-brain barrier. Hexamethylene bisacetamide can induce tumor cell differentiation and inhibit cell proliferation, showing antitumor activity. Hexamethylene bisacetamide induces apoptosis by Notch1, Bcl-2 and p53 signaling pathways. In addition, Hexamethylene bisacetamide improves the obesity phenotype of mice[1][2][3][4][5].
• Target Antigen: Akt; Apoptosis; Bcl-2 Family; Epigenetic Reader Domain; MDM-2/p53; NF-κB; Notch; p38 MAPK
• Type: Reference compound
• Related Pathways: Apoptosis;Epigenetics;MAPK/ERK Pathway;Neuronal Signaling;NF-κB;PI3K/Akt/mTOR;Stem Cell/Wnt
• Field of Research: Cancer; Metabolic Disease; Neurological Disease
• Assay Protocol: https://www.medchemexpress.com/hexamethylene-bisacetamide.html
• Purity: 99.56
• Solubility: DMSO : 25 mg/mL (ultrasonic;warming;heat to 60°C)|H2O : 100 mg/mL (ultrasonic)
• Smiles: CC(NCCCCCCNC(C)=O)=O
• Molecular Weight: 200.28
• References & Citations: [1]Li XN, et al. Modulation effects of hexamethylene bisacetamide on growth and differentiation of cultured human malignant glioma cells. J Neurosurg. 1996 May;84(5):831-8.|[2]Dey A, et al. Hexamethylene bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NF kappaB activity: implications for cancer therapy. Cell Cycle. 2008 Dec;7(23):3759-67.|[3]Cecchinato V, et al. Hexamethylene bisacetamide inhibits malignant phenotype in T-ALL cell lines. Leuk Res. 2008 May;32(5):791-7. https://pubmed.ncbi.nlm.nih.gov/17964649/ |[4]Nilsson LM, et al. Muralidharan SV, Demir D, Welin M, Bhadury J, Logan DT, Walse B, Nilsson JA. Cancer Differentiating Agent Hexamethylene Bisacetamide Inhibits BET Bromodomain Proteins. Cancer Res. 2016 Apr 15;76(8):2376-83.|[5]Park S, et al. HMBA ameliorates obesity by MYH9- and ACTG1-dependent regulation of hypothalamic neuropeptides. EMBO Mol Med. 2023 Dec 7;15(12):e18024.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, protect from light)
• Clinical Information: No Development Reported